Functional cardiomyocytes can now be derived routinely from hPSCs (human pluripotent stem cells), which collectively include embryonic and induced pluripotent stem cells. This technology presents new opportunities to develop pharmacologically relevant in vitro screens to detect cardiotoxicity, with a view to improving patient safety while reducing the economic burden to industry arising from high drug attrition rates. In the present article, we consider the need for human cardiomyocytes in drug-screening campaigns and review the strategies used to differentiate hPSCs towards the cardiac lineage. During early stages of differentiation, hPSC-cardiomyocytes display gene expression profiles, ultra-structures, ion channel functionality and pharmacological responses reminiscent of an embryonic phenotype, but maturation during extended time in culture has been demonstrated convincingly. Notably, hPSC-cardiomyocytes have been shown to respond in a highly predictable manner to over 40 compounds that have a known pharmacological effect on the human heart. This suggests that further development and validation of the hPSC-cardiomyocyte model as a tool for assessing cardiotoxicity is warranted.
Introduction
Unexpected cardiotoxicity underlies the high rates of drug attrition that occur during development and marketing, posing a multi-billion dollar socioeconomic burden on the pharmaceutical industry. From 1990 to 2001, eight non-cardiovascular drugs were withdrawn from clinical use because they prolonged the QT interval, a time that approximates to the duration of the cardiac action potential [1] . This electrophysiological perturbation is dangerous as it has the potential to lead to TdP (torsades de pointes), a condition associated with distortion of transmembrane ion flux, polymorphic ventricular tachyarrhythmia, seizures and sudden death [1] .
It is now widely accepted that the severe attrition seen during screening campaigns is a consequence of suboptimal assays. Early in most development pipelines, drugs are tested for channel-modulating activity by utilizing aneuploid cell lines that overexpress single ion channels. Such assays bear little relation to the complex multichannel phenotype of functional cardiomyocytes [2] . This issue is illustrated by the in vitro culture responses seen with verapamil, a 'safe' drug in routine clinical use for treatment of hypertenstion, angina pectoris and cardiac arrhythmia. In CHO (Chinese-hamster ovary) cells forced to overexpress HERG (human ethera-go-go-related gene), verapamil blocks the I Kr (delayed Key words: cardiomyocyte, drug safety, electrophysiology, human embryonic stem cell, human induced pluripotent stem cell, QT prolongation.
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rectifying potassium current) channel thereby predicting an association with prolonged QT interval [3] . In reality, although outward ion flux through I Kr channels is blocked in functional cardiomyocytes, verapamil also blocks inward flux through L-type calcium channels, and the overall effect on QT interval is cancelled out [3] .
Screens also rely on the use of material derived from animal hearts. However, the relationship between drug responses from animal-derived primary cardiomyocytes for in vitro assays or from tissue samples (e.g. guinea-pig ventricular myocytes) for ex vivo assays and their human counterparts is not always clear [4] . From the human heart itself, harvesting mature cardiomyocytes is confounded by limitations in cell numbers, proliferative capacity, variability in preparation, disease state and viability, especially from cadavers [2] . There also appears to be a population of resident cardiac progenitor cells and there is an ongoing effort to determine whether a suitable population of proliferative cells can be isolated, expanded and differentiated in culture to provide a continual and reproducible supply of cardiomyocytes (for review, see [5] ). In the present article, we review the characteristics of an alternative source of renewable cardiomyocytes, namely those from hPSCs [human PSCs (pluripotent stem cells)], and place particular emphasis on the pharmacological responses that have been reported. embryonic stem cells [7] . Most hiPSC lines have been generated by viral transduction of skin fibroblasts with four key transcription factors that include Oct4 (octamer-binding protein 4) and SOX2 (sex-determining region Y box 2) in combination with Nanog and LIN28 (lin-28 homologue) [8] or c-MYC and KLF4 (Krüppel-like factor 4) [7] . The iPSC field continues to progress rapidly and pluripotency has now been induced by using recombinant virus, recombinant proteins and/or small molecules in many cell types, including those carrying simple or complex genetic diseases [9] [10] [11] .
A key characteristic of hPSCs is their ability to be propagated in culture for extended periods of time and yet be induced to differentiate into a wide range of cell types, including spontaneously beating cardiomyocytes [12] . Early methods of undifferentiated hPSC culture relied on co-culture with mouse embryonic fibroblast feeder layers and the use of labour-intensive mechanical dissection of individual hESC colonies [6] . Cellular substrates have largely been superseded by feeder-free conditions on extracellular biological matrices (e.g. Matrigel TM [12] ) or chemically defined substrates (e.g. poly-D-lysine [13] or plasma-etched polystyrene [14] ). Mechanical dissection has been replaced by bulk passaging with enzymes, such as collagenase, trypsin, accutase or TrypLE [12, 15, 16] . These advances have provided opportunities to test the feasibility of scaled automation of hPSC cultures. Propagation of hESCs through serial passage has been achieved on the Compact SelecT, an industrially relevant robotic platform used routinely by many pharmaceutical companies to harvest >10 9 cells by simultaneously culturing >90× T175 flasks [17] . Similarly, expansion of hESCs has been reported using bioreactor culture [16] . Such scalability has made it possible to initiate pluripotency screens in 384-well plates in an attempt to identify molecules that promote the undifferentiated state [15] . Nevertheless, the field is still challenged by a lack of standardized protocols or reagents and this confounds inter-laboratory translation [18] . Co-ordinated efforts through the International Stem Cell Initiative should facilitate unification [19] .
hPSC-cardiomyocytes
Derivation of cardiomyocytes first from hESCs [20] and later from hiPSCs [21] has been described. The limited number of studies that directly compare cardiomyocyte differentiation in hESCs and hiPSCs have reported a high degree of similarity between differentiation kinetics, gene expression and function, including electrophysiology and pharmacology [21, 22] . For both pluripotent cell types, differentiation is most commonly induced by forming spheroids, known as EBs (embryoid bodies), via spontaneous agglomeration of hPSCs in suspension [23] or via forced aggregation [24, 25] . The latter approach requires centrifugation, but affords greater control of EB size and subsequent differentiation because defined numbers of cells contribute to each EB and provide higher throughput by processing in 96-or 384-well plates.
The timing and number of EBs that start to beat spontaneously varies dramatically depending on the hESC line, culture medium or differentiation strategy. Contraction usually initiates between days 6 and 24 of differentiation in 0-70% of EBs at a rate of 30-130 beats/min. The composition of beating clusters is highly heterogeneous, with cardiomyocytes typically constituting <25% of cells and the remainder comprising endodermal lineages or fibroblasts [26, 27] . Consequently, attempts to induce cardiomyogenesis have been made with small molecules that alter MAPK (mitogen-activated protein kinase) signalling (e.g. SB203580 [28] ) and DNA methylation (e.g. 5-aza-2 -deoxycytidine [29] ). Growth factors have been used in an attempt to mimic the pathways activated during embryonic development, and include activin A, BMP4 (bone morphogenetic protein 4), bFGF (basic fibroblast growth factor), VEGF (vascular endothelial growth factor) and DKK1 (dickkopf homologue 1) [24, 30] . Similar efforts have been applied to differentiation in monolayers [31] , a development that will be important both to reduce the labour involved in producing cardiomyocytes and to integrate the process with automated platforms. Although these strategies have been reported to induce cardiomyocyte differentiation efficiencies of up to 50% [30] , it is still necessary to determine how well they translate between different hPSC lines or laboratories.
Properties of hPSC-cardiomyocytes
Analysis of gene expression shows that differentiation of hPSCs towards beating cardiomyocytes follows a pattern reminiscent of the developing heart in vivo. Pluripotency markers (e.g. OCT4 and NANOG) are down-regulated concurrently with the up-regulation of cardiac transcription factors [e.g. NKX2.5 (NK2 transcription factor-related, locus 5), TBX5 (T-box 5) and MEF2C (myocyte enhancer factor 2C)] and subsequently genes encoding structural proteins [e.g. MYH6 (myosin, heavy polypeptide 6, cardiac muscle α) and MYH7 (myosin, heavy polypeptide 7, cardiac muscle β)] [27, 32] . Correspondingly, immunofluorescence shows the presence of structural proteins, such as α-actinin, but the cardiomyocytes have multi-angular morphologies and relatively disorganized sarcomeric striations [29] . This is similar to the level of organization seen in human fetal cardiomyocytes, but contrasts with adult cardiomyocytes, which have a rod-shaped morphology and parallel bundles of sarcomeres [29, 33, 34] . The notion that hPSC-cardiomyocytes are relatively immature at early stages of differentiation is corroborated by several other additional lines of evidence: ultrastructural analyses rarely show a developed T tubule system [33] ; gap junctions comprise several connexins, including connexin45, which is associated with early stages of in vivo development [34, 35] ; smooth muscle actin is expressed, and this protein is associated with embryonic and fetal, but not adult, cardiomyocytes [29] ; and dose-response curves for isoprenaline, a β 1 /β 2 -adrenoceptor agonist, mirror those of the fetal heart (Table 1 ).
Nevertheless, an increasingly level of pharmacological validation (Table 1) shows the potential utility of hPSC-cardiomyocytes in drug evaluation. Moreover, because hPSCcardiomyocytes can be maintained for at least 5 months in [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] to late (days 20-50) stages of hESC-cardiomyocyte differentiation, both the number and the organization of myofibrils increase, and there is a progressive withdrawal from the cell cycle [33] . Beyond day 50, a high degree of sarcomeric organization is observed, as is evident by the presence of Z-line assembly, as well as A (dark), I (light) and M (middle) bands. Occasionally, a T tubule system forms [36] . Maturation also occurs in the potassium handling machinery. I f , the diastolic current, is present in pacemaker, atrial and ventricular cells, and is encoded by HCN1-HCN4 (hyperpolarizationactivated cyclic nucleotide-gated potassium channels 1-4). The expression of these isoforms changes during development and hESC-cardiomyocytes followed the predicted pattern over a 110-day time course, with the expression of HCN2 remaining constant and that of HCN1 decreasing [37] . Maturation as a function of time in culture may account for some of the discrepancies reported in ion channel function. Both cardiac sodium (Na v 1.5) and L-type calcium channels contribute to depolarization during action potential initiation. However, the contribution from the sodium channel increases during development to transition upstroke velocities from ∼8 V/s in fetal ventricular cardiomyocytes to ∼150-350 V/s in adult cells. In hESC-cardiomyocytes, upstroke velocities of between 4 and 118 V/s have been recorded [34, 37, 38] . Similarly, the contribution of the SR (sarcoplasmic reticulum) in calcium handling also increases during maturation [39] . In normal hearts, caffeine induces the rapid opening of the SR calcium channels, ryanodine inhibits the ryanodine receptor channel and thapsigargin inhibits the SERCA (sarco/endo-plasmic reticulum Ca 2+ -ATPase) pump. However, considerable differences in the pharmacological response of hESC-cardiomyocytes to each of these agents have been reported, from a substantial response to no effect (Table 1) . Discrepancies probably relate to differences in the hESC lines used, the culture and differentiation protocols or the architecture of the cardiomyocytes analysed (i.e. intact beating EBs compared with small clusters of beating cells). This further reinforces the need for unified methods.
If extended culture does not fully resolve the issue of maturation, then an alternative intervention may be necessary. Forced overexpression of calsequestrin has been shown to increase the calcium handling function of the SR [40] . Transplantation of hESC-cardiomyocytes into the working myocardium of mice induces sarcomeric alignment and expression of genes associated with adult cardiomyocytes [41] , suggesting that recreating a suitable environment or increasing electrical/mechanical load will be important parameters to consider in future studies.
Pharmacological responses of hPSC-cardiomyocytes
Muscarinic receptors and adrenoceptors influence heart rate, whereas the waveform of the cardiac action potential is governed by the complex interplay between various calcium, sodium and potassium channels. The presence of various components of the excitation-contraction coupling machinery has been demonstrated by a combination of gene expression, electrophysiological and/or pharmacological analysis (Table 1) . Numerous reports have documented the response of hESC-cardiomyocytes to chronotropic agents. The muscarinic receptor agonists carbamylcholine and acetylcholine reduce beat rate, and the effect of the latter agent can be blocked by competitive inhibitors such as atropine. Similarly, several agents have been used to stimulate or inhibit α 1 -, α 2 -, β 1 -and β 2 -adrenoceptors (Table 1) .
Recently, there have been concerted efforts to investigate the effect of pharmacology on electrophysiology by recording intracellular action potentials via whole-cell patchclamp or extracellular field potentials via MEAs (microelectrode arrays). Many of the drugs selected for evaluation in hPSC-cardiomyocytes (Table 1 ) are known to reduce the flux of sodium and/or potassium ions, which slows the rate of depolarization or repolarization respectively, and leads to prolonged QT interval. Blockade of the HERG (I Kr ) channel by the class III anti-arrhythmic agents E4031 and Sotalol prolonged QT, as predicted ( Figure 1 and Table 1 ). Procainamide blocks sodium channels when they are in the 'open' conformation and simultaneously inhibits potassium channels, an outcome that appears to be mirrored by the response seen in hESC-cardiomyocytes. Quinidine prolongs QT interval by interfering with at least six different sodium and potassium channels, and several reports have shown that treatment of hESC-and hiPSC-cardiomyocytes results in extended action/field potential duration. Other drugs, such as cisapride, that have been withdrawn from the market due to fatalities arising from increased QT interval, elicit similar electrophysiological responses in hESC-cardiomyocytes. Blockade of L-type calcium channels is known to shorten action potential duration, a result seen when hESC-cardiomyocytes were treated with lacidipine or nifedipine ( Table 1 ).
Drugs that interact with an equal efficacy on multiple ion channels involved in depolarization and repolarization, and hence have limited overall net effect on QT interval, have also been tested in hPSC-cardiomyocytes. As predicted, only physiologically excessive doses (0.1-1 μM) of verapamil, a blocker of potassium (I Kr ) and L-type calcium channels, prolonged the field potential ( Table 1 ). The net effect of ranolazine on QT interval is mild in the working heart, probably because the mechanism of action is proposed to be dual inhibition of I Kr and late I Na (sodium current) [42] . Our findings show a negligible effect on field potential duration of hESC-cardiomyocytes treated with ranolazine, although the waveform during repolarization does change at higher doses ( Figure 1) .
Unquestionably, these proof-of-principle studies are encouraging. However, only one study [26] has performed a detailed dose-response analysis to show that the serum levels in patients of drugs with known effects on QT interval overlapped with prolonged MEA field potential duration derived from hESC-cardiomyocytes. Clearly, considerable research is needed before pharmaceutical companies will be Beating clusters of HUES7-derived cardiomyocytes were seeded on to MEAs and challenged with increasing doses of (A) E4031, a class III anti-arrhythmic I Kr channel blocker, or (B) ranolazine, a dual inhibitor of I Kr and late I Na channels.
Representative field potential traces are shown in (Ai) and (Bi). The horizontal bar represents 0.5 s and the vertical bar represents 500 μV. The expanded traces show prolongation of field potential duration in response to E4031 (Aii) and altered waveform to ranolazine (Bii). The influence of drug dose on field potential (FP) duration is shown in (Aiii) and (Biii).
confident enough to integrate hPSC-cardiomyocytes into development strategies.
Enrichment of hESC-cardiomyocytes
Another potential issue is the lack of purity of the hPSCcardiomyocyte assay material. Most reports have tested drugs on beating clusters that contain at most 25% cardiomyocytes, which themselves comprise a heterogeneous population of atrial, ventricular and pacemaker subtypes. Therefore recent efforts have been to develop strategies that enrich for cardiomyocytes and/or particular subtypes. The ventricular subtype is considered most relevant to the pharmaceutical industry because of the association of drug-induced QT prolongation with the polymorphic ventricular tachycardia TdP [1, 2] .
Mechanical dissection of beating areas is of limited use and lack of appropriate cardiomyocyte-specific surface markers means FACS sorting is not currently possible [27] . Centrifugation through a Percoll gradient enables partial enrichment, but is non-specific and non-cardiomyocyte cell types remain [29] . Transgenic enrichment has been successful; in hESC lines expressing αMHC-puro [27] or MLC2v-GFP [43] cassettes, treatment with puromycin or sorting by FACS yielded cardiomyocytes of 92 and 93% purity respectively. Most recently, selective enrichment to 99% purity has been achieved by combining FACS sorting with MitoTracker dyes, with the rationale being that cardiomyocytes are the cells that host the highest numbers of mitochondria [44] . Attention has also been directed towards development of hPSC-derived cardiac progenitor cell lines [45] , although it remains to be seen whether these SSEA1 (stage-specific embryonic antigen 1) + Oct4 + cells can be propagated in culture and subsequently differentiated into functional cardiomyocytes.
Isolation of ventricular subtypes is an area that requires further attention. Most protocols for hPSC differentiation result in the formation of beating clusters that comprise approximately equal yields of ventricular and non-ventricular cells [23, 27] . The proportion of ventricular cells can be increased to ∼85% by co-culturing hPSCs with mouse END-2 cells, a visceral endoderm-like mouse cell line [34] . The rational for this approach is that endoderm instructs mesoderm/cardiac formation during embryonic development. However, scalability of this strategy may be problematic because hESC colonies are harvested mechanically prior to co-culture with END-2 cells. Transgenic reporter/ventricular promoters {e.g. MLC2v (ventricular myosin light chain 2), PLN (phospholamban) and RYR2 (ryanodine receptor 2) [46] } may prove a viable approach. Alternatively, development of next-generation technologies such as Raman micro-spectrocopy may allow label-free non-invasive isolation of ventricular myocytes. Although this is an earlystage technology, it has been used successfully to distinguish hESC-cardiomyocytes from non-cardiomyocytes on the basis of the vibrational spectrum that arises from the interaction of laser light with molecules in the cells [47] .
Conclusions
The preliminary characterization of hPSC-cardiomyocytes and their validation with over 40 drugs of known activity suggests that these cells could serve as a new tool for predicting cardiotoxicity. The key challenges that lie ahead will include improving reproducibility of differentiation between different hPSC lines, between laboratories and even between experiments within the same hPSC line [18] . Cost-effective 1000-fold increases in yields of hPSC-cardiomyocytes are also required to translate laboratory-based production to that demanded by industry and this will necessitate integration with robotic platforms. Scalability from manual patch-clamp and single-well MEAs to automated high-throughput platforms, such as PatchXpress, IonWorks and QT-screen [3] , needs to be demonstrated. Regulators will also require detailed doseresponse curves and inclusion of analytical standards that are industrially relevant. This will include readouts such as alterations in action potential duration (APD 30 ) to report on I Ca (caclium current) function and APD 40−90 (known as triangulation) on I K (potassium current) [4] , and how these outputs relate to existing models. On the other hand, there are tremendous opportunities to improve safety by in vitro screening that will probably include hiPSC-derived genotypes from patients with known susceptibility to drugs.
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